The global atopic dermatitis drugs market to grow at a CAGR of 4.20% during the period 2017-2021.
Global Atopic Dermatitis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers the revenue generated from the sales of atopic dermatitis drugs.
According to the report, atopic dermatitis is one of the most common forms of inflammatory skin diseases. Food allergy and severe atopic dermatitis coexist in approximately one-third of all children with atopic dermatitis. According to research studies, 5%-10% of all children have atopic dermatitis, and one-third of them have a food allergy. Globally, among babies aged three to 18 months with mild atopic dermatitis, 15% have certain food allergies. Research studies show that the early onset of severe atopic dermatitis in infancy is related to high risk of IgE food sensitization, which is commonly associated with food allergy.
Atopic dermatitis is affected by genetic and environmental factors. Biologic agents for moderate to severe atopic dermatitis provide control over the disease. The market currently lacks good and safe therapeutics, which increases the large unmet need. Biologics targeting adaptive immune responses have been tested in patients with atopic dermatitis who do not respond to other treatments.
Further, the report states that the FDA regulates the medicines used by the US public. Black box warnings are put in the labeling of prescription drugs or drug products, by the FDA, to warn users of serious hazards associated with the drug. This warning is issued when the FDA receives reports of adverse events related to drug usage after it has been approved.
- Growing prevalence of food allergies exacerbating atopic dermatitis
- Growing focus on systemic therapies
- Increasing use of pharmacological products in developing countries
- Black box warning for Elidel and Protopic
- Highly genericized market
- Poor patient adherence due to inadequate information on drug usage
- Increasing M&A leading to market consolidation
- Launch of first biologic for atopic dermatitis
- Growing focus on novel drugs
- LEO Pharma
- Bayer HealthCare
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Research Methodology
Part 04: Introduction
Part 05: An overview of atopic dermatitis
Part 06: Pipeline analysis
Part 07: Market landscape
Part 08: Five force analysis
Part 09: Market segment by ROA
Part 10: Geographical segmentation
Part 11: Market drivers
Part 12: Impact of drivers
Part 13: Market challenges
Part 14: Impact of drivers and challenges
Part 15: Market trends
Part 16: Vendor landscape
Part 17: Appendix
For more information about this report visit http://www.researchandmarkets.com/research/34t8mn/global_atopic